Semaglutide — The Defining GLP-1 Agonist

Background

Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk, with a half-life of approximately 7 days that supports once-weekly subcutaneous dosing. It is licensed as Ozempic® and Rybelsus® for type 2 diabetes, and as Wegovy® for chronic weight management.

Mechanism

Semaglutide is a GLP-1 analogue modified at three positions (Aib substitution at position 8, fatty-acid C18 side-chain at position 26, Lys-Arg swap at position 34) to resist DPP-4 cleavage and bind albumin, extending its half-life. It produces glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite circuits.

What is proven

The SUSTAIN program (>10,000 participants across SUSTAIN 1–10) demonstrated robust HbA1c reduction and modest weight loss in T2D versus placebo and active comparators.

STEP 1 (2021, NEJM) reported mean weight loss of ~14.9% at 68 weeks in adults with obesity without T2D on 2.4 mg weekly semaglutide.

The SELECT trial (2023, NEJM) showed a 20% relative reduction in major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight/obesity.

FLOW (2024) reported kidney-outcome benefit in patients with T2D and chronic kidney disease.

What is NOT proven (for research-grade material)

Research-grade semaglutide sold for in-vitro use is not the licensed pharmaceutical product. Identity, purity (peptide impurities, residual solvents), endotoxin content, sterility, and dose accuracy outside a regulated pharmaceutical supply chain are not guaranteed by any pharmacopoeial standard.

Long-term safety signals around lean-mass loss, bone density, pancreatitis (debated), and post-discontinuation weight regain continue to be studied even for the licensed product.

Open research questions

Long-term cardiovascular and renal benefit in non-diabetic obesity beyond the SELECT and FLOW timeframes; effect on neurodegenerative endpoints (Alzheimer's trials are ongoing); optimal strategies for lean-mass preservation during rapid weight loss.

Regulatory status

Approved by the FDA, EMA, MHRA and other major regulators for type 2 diabetes (2017) and chronic weight management (2021). Cardiovascular indication added on the basis of SELECT (2024).

All Proteus® compounds are sold strictly for in-vitro research. Nothing on this page is medical advice, a treatment claim, or a recommendation for human use. Where compounds are licensed medicines in any jurisdiction, that approval applies to the licensed product supplied through a regulated pharmacy — not to research-grade material.